Deals

Monika Paulė (Caszyme) and Dr Avencia Sánchez-Mejías (Integra Therapeutics) at BIO-Europe in Stockholm

Partnerships underpin the CRISPR revolution, says Caszyme CEO Partnerships underpin the CRISPR revolution, says Caszyme CEO

Integra Therapeutics will use Caszyme’s genome editor Cas12l in its FiCAT 2.0 gene-writing platform to develop safer and more effective cell and gene therapies.

byMillie Nelson, Editor

Jan 30, 2025

|

1 Min Read

The word ONCOLOGY is written on wooden cubes near a stethoscope

Lilly taking sting out of Scorpion in $2.5bn cancer drug buy Lilly taking sting out of Scorpion in $2.5bn cancer drug buy

byMillie Nelson

Jan 24, 2025

1 Min Read

Asia on a world globe

Eyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPM Eyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPM

Jan 21, 2025

1 Min Read

magnifying glass focused on China flag

China biopharma development still hot & still expanding its reach China biopharma development still hot & still expanding its reach

byRichard Daverman

Jan 21, 2025

1 Min Read

the word deal written on blue blocks in white writing

JPM 2025: Gilead inks inflammatory deal with LEO JPM 2025: Gilead inks inflammatory deal with LEO

byMillie Nelson

Jan 20, 2025

1 Min Read

Novo Nordisk logo on a window

Business Strategy

Novo on the ‘ins and outs’ of its nucleic acid growth Novo on the ‘ins and outs’ of its nucleic acid growth

Jan 16, 2025

1 Min Read

dollar bills

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

byMillie Nelson, Editor

JPM written on wooden blocks in blue

JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx

JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx

byMillie Nelson, Editor

Image of China banknotes with a magnifying glass indicating dealmaking in Asia

Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung

Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung

byDan Stanton, Editorial director

2025 wooden blocks

Takeovers, Trump, and trends: how biopharma is likely to shift this year

Takeovers, Trump, and trends: how biopharma is shifting this year

byJonathan Smith

M&A on wooden blocks

AbbVie forks out $200m to buy Roche spin-out Nimble

AbbVie forks out $200m to buy Roche spin-out Nimble

byMillie Nelson, Editor

2024 on a road

Megadeals continued amid sluggish investments and M&A in 2024

Megadeals continued amid sluggish investments and M&A in 2024

byJonathan Smith

Asia currency

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

byRichard Daverman, Editor

Trust on a dial

Three’s a crowd? Not in this partnership, says MicroFluidX

Three’s a crowd? Not in this partnership, says MicroFluidX

byMillie Nelson, Editor

Currency

Eyes on Asia: Merck and BioNTech land Chinese bispecifics

Eyes on Asia: Merck and BioNTech land Chinese bispecifics

byRichard Daverman, Editor

The ELA'S 2024

LSX awards the crème de la crème of dealmaking

LSX awards the crème de la crème of dealmaking

byMillie Nelson, Editor

Shaking hands

Picky pharma prone to better proven partners amid dealmaking downturn

Picky pharma prone to better proven partners amid dealmaking downturn

byMillie Nelson, Editor

Money

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

byRichard Daverman, Editor

Money

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman, Editor

Asian currency

Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

byRichard Daverman, Editor

Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?

News from Sanofi, Bayer, AZ plus the return of VC?

byRichard Daverman, Editor

To be truly great you need to partner, says J&J

To be truly great you need to partner, says J&J

byMillie Nelson, Editor

Oncology

Bayer and NextRNA: One partnership, two oncology programs

Bayer and NextRNA: One partnership, two oncology programs

byMillie Nelson, Editor

Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more

Shinyaku’s $735m DMD deal, Kite turns back in China, and more

byRichard Daverman, Editor

Chinese flag — Photo

China biopharma faces a pause; how bad is it?

China biopharma mid-2023 market summary

byRichard Daverman, Editor

Illustration, Science word. Business concept for Study of physical world structure behavior Experimental research — Illustration

European drug discovery and development players showcase their science at BIO-Europe 2023

European drug discovery and development players showcase their science

Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA march

Eyes on Asia: News from EpimAb, TargetRx, Hygieai

byRichard Daverman, Editor

Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun

Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun

byRichard Daverman, Editor

BIO-Europe Spring

Competitor today, friend tomorrow: Why partnering is critical for biopharma success

Why partnering is critical for biopharma success

byMillie Nelson, Editor

Mounajro

GLP-1 boom causing pharma players FOMO

GLP-1 boom causing pharma players FOMO

byMillie Nelson, Editor

Broken heart

It’s not me, it’s you! Experts on when you should dump your CDMO

Experts on when you should dump your CDMO

byMillie Nelson, Editor

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.